Literature DB >> 17627412

From outside to inside? Dose-dependent renal tubular damage after high-dose peptide receptor radionuclide therapy in rats measured with in vivo (99m)Tc-DMSA-SPECT and molecular imaging.

Flavio Forrer1, Edgar Rolleman, Magda Bijster, Marleen Melis, Bert Bernard, Eric P Krenning, Marion de Jong.   

Abstract

UNLABELLED: In peptide receptor radionuclide therapy (PRRT), the dose-limiting organ is, most often, the kidney. However, the precise mechanism as well as the exact localization of kidney damage during PRRT have not been fully elucidated. We studied renal damage in rats after therapy with different amounts of [(177)Lu-DOTA(0), Tyr(3)]octreotate and investigated (99m)Tc-DMSA (dimercaptosuccinic acid) as a tool to quantify renal damage after PRRT. EXPERIMENTAL
DESIGN: Twenty-nine (29) rats were divided into 3 groups and injected with either 0, 278, or 555 MBq [(177)Lu-DOTA(0), Tyr(3) ]octreotate, leading to approximately 0, 46, and 92 Gy to the renal cortex. More than 100 days after therapy, kidney damage was investigated using (99m)Tc-DMSA single-photon emission computed tomography (SPECT) autoradiography, histology, and blood analyses.
RESULTS: In vivo SPECT with (99m)Tc-DMSA resulted in high-resolution (<1.6-mm) images. The (99m)Tc-DMSA uptake in the rat kidneys was inversely related with the earlier injected activity of [(177)Lu-DOTA(0), Tyr(3)]octreotate and correlated inversely with serum creatinine values. Renal ex vivo autoradiograms showed a dose-dependent distribution pattern of (99m)Tc-DMSA. (99m)Tc-DMSA SPECT could distinguish between the rats that were injected with 278 or 555 MBq [(177)Lu-DOTA(0), Tyr(3) ]octreotate, whereas histologic damage grading of the kidneys was nearly identical for these 2 groups. Histologic analyses indicated that lower amounts of injected radioactivity caused damage mainly in the proximal tubules, whereas as well the distal tubules were damaged after high-dose radioactivity.
CONCLUSIONS: Renal damage in rats after PRRT appeared to start in a dose-dependent manner in the proximal tubules and continued to the more distal tubules with increasing amounts of injected activity. In vivo SPECT measurement of (99m)Tc-DMSA uptake was highly accurate to grade renal tubular damage after PRRT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17627412     DOI: 10.1089/cbr.2006.353

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  7 in total

1.  Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate.

Authors:  Amir Sabet; Khaled Ezziddin; Ulrich-Frank Pape; Karl Reichman; Torjan Haslerud; Hojjat Ahmadzadehfar; Hans-Jürgen Biersack; James Nagarajah; Samer Ezziddin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-06       Impact factor: 9.236

2.  Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours.

Authors:  Amir Sabet; Torjan Haslerud; Ulrich-Frank Pape; Amin Sabet; Hojjat Ahmadzadehfar; Frank Grünwald; Stefan Guhlke; Hans-Jürgen Biersack; Samer Ezziddin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-09-13       Impact factor: 9.236

3.  Potential Biomarkers for Radiation-Induced Renal Toxicity following 177Lu-Octreotate Administration in Mice.

Authors:  Emil Schüler; Maria Larsson; Toshima Z Parris; Martin E Johansson; Khalil Helou; Eva Forssell-Aronsson
Journal:  PLoS One       Date:  2015-08-19       Impact factor: 3.240

4.  Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of (161)Tb-folate and (177)Lu-folate.

Authors:  Stephanie Haller; Giovanni Pellegrini; Christiaan Vermeulen; Nicholas P van der Meulen; Ulli Köster; Peter Bernhardt; Roger Schibli; Cristina Müller
Journal:  EJNMMI Res       Date:  2016-02-09       Impact factor: 3.138

5.  Intratumoral administration of holmium-166 acetylacetonate microspheres: antitumor efficacy and feasibility of multimodality imaging in renal cancer.

Authors:  Wouter Bult; Stephanie G C Kroeze; Mattijs Elschot; Peter R Seevinck; Freek J Beekman; Hugo W A M de Jong; Donald R A Uges; Jos G W Kosterink; Peter R Luijten; Wim E Hennink; Alfred D van het Schip; J L H Ruud Bosch; J Frank W Nijsen; Judith J M Jans
Journal:  PLoS One       Date:  2013-01-08       Impact factor: 3.240

6.  Influence of tumour size on the efficacy of targeted alpha therapy with (213)Bi-[DOTA(0),Tyr(3)]-octreotate.

Authors:  Ho Sze Chan; Mark W Konijnenberg; Erik de Blois; Stuart Koelewijn; Richard P Baum; Alfred Morgenstern; Frank Bruchertseifer; Wouter A Breeman; Marion de Jong
Journal:  EJNMMI Res       Date:  2016-01-20       Impact factor: 3.138

7.  Nephroprotective effects of enalapril after [177Lu]-DOTATATE therapy using serial renal scintigraphies in a murine model of radiation-induced nephropathy.

Authors:  Harun Ilhan; Hao Wang; Franz J Gildehaus; Carmen Wängler; Tanja Herrler; Andrei Todica; Julia Schlichtiger; Paul Cumming; Peter Bartenstein; Marcus Hacker; Alexander R Haug
Journal:  EJNMMI Res       Date:  2016-08-11       Impact factor: 3.138

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.